Reactive oxygen species generation and the total antioxidant status in patients with chronic obstructive pulmonary disease and community-acquired pneumonia
https://doi.org/10.18093/0869-0189-2018-28-3-307-312
Abstract
The objective of this study was to investigate reactive oxygen species (ROS) generation and the total antioxidant status (TAOS) in patients with chronic obstructive pulmonary disease (COPD) and community-acquired pneumonia (CAP). Methods. Fifty-five hospitalized patients with COPD were involved in the study. The patients were divided into two groups: patients with acute exacerbation of COPD (COPD group; n = 28), and patients with COPD and CAP (COPD + CAP group; n = 27). Severity of symptoms, clinical and laboratory findings were analyzed. ROS generation was assessed using the luminol-dependent chemiluminescence (ChL) of the blood. TAOS was evaluated in the blood serum using TAS RANDOS kit (RANDOX laboratory Ltd., GB). Results. Both spontaneous and pyrogenal-induced ChLs in the blood were reduced in all patients that indicated reduced ROS generation. TAOS was also decreased. The intensity of ChL and TAOS were related to lung function and serum level of C-reactive protein. After treatment, the inflammation has not been resolved and abnormal TAOS and ROS were still detected. Conclusion. CAP in patients with COPD and the acute exacerbation of COPD were associated with reduction in ROS generation and TAOS in the blood. Clinical symptoms were more prominent, C-reactive protein level was higher, and TAOS was lower in COPD + CAP patients compared to patients with acute exacerbation of COPD.
About the Authors
Yu. R. Farkhutdinov
Bashkir Federal State Medical University;
Ufa City State Teaching Hospital No.21
Russian Federation
Russian Federation
Usman R. Farkhutdinov, Doctor of Medicine, Professor, Department of Propaedeutics of Internal Diseases, Bashkir Federal State Medical University, Healthcare Ministry of Russia; Head of Department of Pulmonology, Ufa City State Teaching Hospital No.21
ul. Lenina 3, Ufa, 450000, Bashkortostan Republic,
Lesnoy proyezd 3, Ufa, 450071, Bashkortostan Republic
Е. F. Amirova
Ufa City State Teaching Hospital No.21
Russian Federation
Russian Federation
El’mira F. Amirova, a physician, Department of Pulmonology
Lesnoy proyezd 3, Ufa, 450071, Bashkortostan Republic
R. R. Farkhutdinov
Bashkir Federal State Medical University
Russian Federation
Russian Federation
Rafagat R. Farkhutdinov, Doctor of Medicine, Professor, Leading Researcher, Central Research Laboratory
ul. Lenina 3, Ufa, 450000, Bashkortostan Republic
References
1. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Russian Respiratory Society. Federal Guidelines on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease. Pul’monologiya. 2014; (3): 15–54. DOI: 10.18093/0869-0189-2014-0-3-15-54 (in Russian).
2. Baymakova G.E., Zubairova P.A., Avdeev S.N., Chuchalin A.G. Clinical symptoms and course of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Pul’monologiya. 2009; (2): 33–41 (in Russian).
3. Kuzubova N.A., Titova O.N., Volchkov V.A., Kozyrev A.G. Clinical course of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Trudnyy patsiyent. 2014; 12 (3). Available at: http://t-pacient.ru/articles/8163/ [Accessed February 07, 2018] (in Russian).
4. Bruns A.H., Oosterheert J.J., Cucciolillo M.C. et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia compared with the general Dutch population. Clin. Microbiol. Infect. 2011; 17 (5): 763–768. DOI: 10.1111/j.1469-0691.2010.03296.x.
5. Shikhnebiyev D.A. Clinical course and diagnosis of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Sovremennyye problemy nauki i obrazovaniya. 2014; (2). Available at: https://science-education.ru/ru/article/view?id=12720 [Accessed February 07, 2018] (in Russian).
6. Rajendrasozhan S., Yang S.R., Edirisinghe I. et.al. Deacetylases and NF-κB in redox regulation of cigarette smoke induced lung inflammation: Implications in pathogenesis of COPD. Antioxid. Redox Signal. 2008; 10 (4): 799–811. DOI: 10.1089/ars.2007.1938.
7. Rahman I., Marwick J., Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and proinflammatory gene expression. Biochem. Pharmacol. 2004; 68 (6): 1255–1267. DOI: 10.1016/j.bcp.2004.05.042.
8. Gabitova D.M. A role of free-radical oxidation for occurrence of COPD and lung carcinomas. Sovremennyye problemy nauki i obrazovaniya. 2015; (6). Available at: https://science-education.ru/ru/article/view?id=24032 [Accessed February 07, 2018] (in Russian).
9. Bargagli E., Olivieri C., Bennett D. et al. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir. Med. 2009; 103 (9): 1245–1256. DOI: 10.1016/j.rmed.2009.04.014.
10. Chuchalin A.G., Sinopal’nikov A.I, Strachunskiy L.S. et al. Community-acquired pneumonia in adults: a practical handbook on diagnosis, treatment and prevention. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2006; 8 (1): 54–86 (in Russian).
11. Levy M.L., Le Jeune I., Woodhead M.A. et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim. Care Respir. J. 2010; 19 (1): 21–27. DOI: 10.4104/pcrj.2010.00014.
12. Charlson M.E., Pompei P., Ales K.L., McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40 (5): 373–383.
13. Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax.1999; 54 (7): 581–586.
14. Kunitsina Yu.L., Shmelev E.I. Antiinflammatory therapy of chronic obstructive pulmonary disease. Pul’monologiya. 2003; (2): 111–116 (in Russian).
15. Miller N.J., Rice-Evans C., Davies M.J. et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci. (Lond.).1993; 84 (4): 407–412.
16. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106 (2): 196–204. DOI: 10.7326/0003-4819-106-2-196.
17. Gallorini M., Petzel C., Bolay C. et al. Activation of the Nrf2-regulated antioxidant cell response inhibits HEMA-induced oxidative stress and supports cell viability. Biomaterialis. 2015; 56: 114–128. DOI: 10.1016/j.biomaterials.2015.03.047.
18. Zenkov N.K., Men’shchikova E.B. Active oxygen metabolites are the main weapon of phagocytes to resist microorganisms. In: Reactive oxygen species, nitric oxide, antioxidants and human diseases, The 4th National Scientific and Practical Conference with International Participation. Collected papers. Smolensk: OAO "Smolenskoblgaz"; 2005: 32–35 (in Russian).
19. Men’shchikova E.B., Lankin V.Z., Zenkov N.K., eds. Oxidative Stress. Oxidants and Antioxidants. Moscow: Slovo; 2006 (in Russian).
20. Farkhutdinov U., Farkhutdinov Sh., Oleinick L. Antioxidant activity of anticholinergic bronchodilatators. Eur. Respir. J. 2008; 32 (Suppl. 52): 643s.
Review
For citations:
Farkhutdinov Yu.R., Amirova Е.F., Farkhutdinov R.R. Reactive oxygen species generation and the total antioxidant status in patients with chronic obstructive pulmonary disease and community-acquired pneumonia. PULMONOLOGIYA. 2018;28(3):307-312. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-3-307-312
Views:
1584
Email this article 